NR
NRIX.US Nurix Therapeutics Inc
- Market cap
- USD 1.69B
- P/E
- 6.4x
- P/B
- 1.74x
- ROE
- 51.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2026.
Is NRIX.US undervalued?
Graham numberNRIX.US trades 29.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nurix Therapeutics Inc fundamental analysis
No fundamental analysis for Nurix Therapeutics Inc yet.
Nurix Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's ty…
Full company profileNurix Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nurix Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 37.4M | 31.1M | 17.8M | 29.8M | 38.6M | 77.0M | 54.5M | 84.0M | 918M |
| Gross Profit | -3.07M | -13.9M | 17.8M | 29.8M | 38.6M | -112M | -167M | 65.1M | 798M |
| Operating Income | -9.74M | -22.2M | -65.0M | -118M | -184M | -155M | -213M | -286M | 497M |
| EBITDA | -6.75M | -19.9M | -62.8M | -112M | -173M | -130M | -177M | -245M | 528M |
| Net Income | -9.43M | -21.7M | -43.2M | -117M | -166M | -144M | -194M | -264M | 497M |
| EPS | -0.59 | -0.56 | -2.76 | -2.73 | -3.42 | -2.65 | -2.88 | -3.05 | 4.28 |
| Balance Sheet | |||||||||
| Total Assets | 45.4M | 44.0M | 396M | 477M | 417M | 356M | 669M | 688M | 1.20B |
| Total Liabilities | 34.0M | 53.6M | 106M | 134M | 113M | 155M | 142M | 149M | 227M |
| Shareholders' Equity | -36.8M | -57.7M | 290M | 342M | 304M | 200M | 527M | 539M | 968M |
| Cash & Short-term Investments | 39.0M | 37.7M | 281M | 296M | 309M | 288M | 610M | 593M | 1.05B |
| Total Debt | - | - | - | 13.0M | 12.0M | 30.6M | 28.3M | 55.7M | 65.3M |
| Cash Flow | |||||||||
| Operating Cash Flow | -31.7M | 601K | -80.0K | -84.4M | -160M | -81.4M | -173M | -249M | 596M |
| Capital Expenditure | 1.60M | 1.65M | 4.55M | 5.66M | 12.2M | 8.40M | 9.27M | 14.0M | 5.83M |
| Free Cash Flow | -33.3M | -1.05M | -4.63M | -90.0M | -172M | -89.8M | -182M | -263M | 590M |
| Ratios | |||||||||
| ROE | - | - | -14.9% | -34.2% | -54.7% | -71.8% | -36.7% | -49.1% | 51.4% |
| ROA | -20.8% | -49.3% | -10.9% | -24.6% | -39.8% | -40.5% | -28.9% | -38.4% | 41.6% |
| Net Profit Margin | -25.2% | -69.7% | -242.7% | -393.9% | -429.9% | -187.0% | -354.9% | -314.9% | 54.2% |
| Debt to Equity | - | - | - | 0.04x | 0.04x | 0.15x | 0.05x | 0.10x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nurix Therapeutics Inc dividends
Nurix Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Who owns Nurix Therapeutics Inc
- Insiders 1.59%
- Institutions 98.41%
- Public & others 0.00%
- Shares outstanding 109M
- Free float 79.6M
Top funds holding NRIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.30M | 3.02% | +0.38% | Sep 2026 |
| iShares Russell 2000 ETF | 2.42M | 2.22% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.35M | 2.15% | +2.69% | Oct 2026 |
| ARK Genomic Revolution ETF | 2.35M | 2.15% | +0.58% | Oct 2026 |
| American Funds SMALLCAP World A | 1.74M | 1.59% | 0.00% | Sep 2026 |
| Pictet-Biotech P USD | 1.42M | 1.30% | -9.31% | Jul 2026 |
| Eventide Healthcare & Life Sciences I | 1.30M | 1.19% | 0.00% | Jun 2026 |
| Fidelity Small Cap Index | 1.05M | 0.96% | +0.16% | Aug 2026 |
| T. Rowe Price Health Sciences | 1.04M | 0.95% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 948K | 0.87% | 0.00% | Aug 2026 |
| T. Rowe Price New Horizons | 889K | 0.81% | -11.03% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 824K | 0.75% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 770K | 0.71% | -0.19% | Oct 2026 |
| Handelsbanken Hälsovård (A1 SEK) | 700K | 0.64% | -6.67% | Oct 2026 |
| Amova ARK Pstv Chg Innovt P JPY Acc | 697K | 0.64% | -3.65% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 693K | 0.63% | -0.38% | Oct 2026 |
| Fidelity Growth Company Fund | 645K | 0.59% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 557K | 0.51% | +1.12% | Sep 2026 |
| Vanguard Explorer Inv | 536K | 0.49% | -7.97% | Sep 2026 |
| Belfius Equities Cure C Cap | 534K | 0.49% | 0.00% | Apr 2026 |
Top institutions holding NRIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 8.77M | 8.03% | -1.74% | Jun 2026 |
| Vestal Point Capital LP | 8.05M | 7.37% | +23.85% | Jun 2026 |
| Deep Track Capital, LP | 7.74M | 7.08% | +21.93% | Jun 2026 |
| Rubric Capital Management LP | 7.23M | 6.62% | +192.16% | Jun 2026 |
| FMR Inc | 5.49M | 5.02% | -1.01% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 5.44M | 4.98% | +65.23% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.76M | 4.36% | -3.44% | Jun 2026 |
| State Street Corp | 4.68M | 4.28% | -9.02% | Jun 2026 |
| Baker Bros Advisors LP | 4.66M | 4.26% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.50M | 4.11% | +1.55% | Jun 2026 |
| Perceptive Advisors LLC | 4.32M | 3.95% | +16.43% | Jun 2026 |
| Redmile Group, LLC | 4.07M | 3.73% | -47.32% | Jun 2026 |
| General Atlantic Llc | 3.03M | 2.78% | -26.08% | Jun 2026 |
| Geode Capital Management, LLC | 2.54M | 2.32% | +0.68% | Jun 2026 |
| Pictet Asset Manangement SA | 2.35M | 2.15% | -13.75% | Jun 2026 |
| ARK Investment Management LLC | 1.79M | 1.64% | +4.19% | Jun 2026 |
| Capital World Investors | 1.79M | 1.64% | +100.14% | Jun 2026 |
| Trails Edge Capital Partners, LP | 1.57M | 1.44% | -9.75% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.48M | 1.36% | +34.53% | Jun 2026 |
| Citadel Advisors Llc | 1.48M | 1.35% | +9.92% | Jun 2026 |
Nurix Therapeutics Inc company profile
- Company name
- Nurix Therapeutics Inc
- Ticker
- NRIX.US
- Exchange
- USA Stocks
- Listed since
- Jul 24, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 317
- Fiscal year end
- November
- Address
- 1600 Sierra Point Parkway, Brisbane, CA, United States, 94005
- Phone
- 415 660 5320
- Website
- nurixtx.com
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Nurix Therapeutics Inc management
10- Dr. Arthur T. Sands M.D., Ph.D.CEO, President & Director · born 1962
- Mr. Johannes Van HouteChief Financial Officer · born 1967
- Dr. Gwenn M. Hansen Ph.D.Chief Scientific Officer · born 1971
- Dr. Christine Ring J.D., Ph.D.Chief Legal Officer, Secretary & Chief Compliance Officer · born 1965
- Dr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory Board
- Dr. Arthur Weiss M.D., Ph.D.Founder & Member of Scientific Advisory Board
- Rita KwongSenior Accounting Manager
- Dr. Pasit Phiasivongsa Ph.D.Chief Technical Officer
- Mr. Wesley BurwellChief Human Resources Officer
- Dr. Jason Kantor Ph.D.Chief Business Officer